
|Videos|March 11, 2019
Combining Immunotherapy and Chemotherapy in Patients With SCLC
Author(s)Julie R. Brahmer, MD
Julie R. Brahmer, MD, discusses data for atezolizumab plus platinum/etoposide versus platinum/etoposide alone in patients with small cell lung cancer in the IMpower133 trial.
Advertisement
Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Medicine, discusses data for atezolizumab (Tecentriq) plus carboplatin/etoposide versus carboplatin/etoposide alone in patients with small cell lung cancer (SCLC) in the IMpower133 trial.
Brahmer says these data showed that the addition of the immunotherapy improved progression-free survival in these patients. However, it did not improve the response rate.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















